Able Wealth Management’s Akero Therapeutics AKRO Stock Holding History

Able Wealth Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-34	Closed	-$794	–	105
2023 Q4	$794	Buy	+34	New	+$671	﹤0.01%	532

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Able Wealth Management's AKRO Position: Q1 2024 in Review

Able Wealth Management sold out of Akero Therapeutics (AKRO) in Q1 2024, closing a stake of 34 shares — an estimated $794 sold.

Able Wealth Management first reported a position in AKRO in Q4 2023 and held it in 1 quarter. The position peaked at $794 in Q4 2023. 173 funds tracked by Wall St. Rank hold AKRO as of Q1 2024.

Able Wealth Management reported no remaining Akero Therapeutics position as of Q1 2024 after selling out during the quarter.
Able Wealth Management sold 34 Akero Therapeutics shares in Q1 2024, an estimated $794.
Able Wealth Management first reported a position in Akero Therapeutics in Q4 2023 and held it in 1 quarter.
Able Wealth Management's Akero Therapeutics position peaked at $794 in Q4 2023.
173 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2024.

Based on Able Wealth Management's 13F filing for Q1 2024, filed 1 Nov 2024.